Xeris Pharmaceuticals | XERS - Current Liabilities


Xeris Pharmaceuticals reported $134.48M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Celltrion KRW 288.01B 4.7B Jun/2026
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 28.51M 5.87M Sep/2026
Divis Laboratories Ltd INR 27.07B 6.64B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Kangmei Pharma CNY 5.1B 280.48M Jun/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
Organigram Holdings CAD 107.28M 18.54M Jun/2026
Ovoca Bio EUR 1.3M 1.11M Dec/2025
Pacira USD 126.1M 4.08M Sep/2026
Perrigo USD 1.02B 34.4M Sep/2026
Pharma Mar EUR 125.39M 26.97M Sep/2026
Qiagen NV USD 581.45M 102.34M Jun/2026
Sartorius EUR 1.55B 102.8M Sep/2026
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026
Tilray USD 259.32M 8.32M Sep/2025
Zealand Pharma A/S 404M 260.96M Mar/2026
Zz Pientze Pharmaceu CNY 2.74B 277.02M Sep/2026